Position in LGND
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$42,039
+$15,486 QoQ
Shares Held
133
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#348
of 413 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LGND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Millstone Evans Group, LLC holds $105,206 across 10 Biotechnology names. LGND ranks #1 (40.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
This page
|
133 | $42,039 | |
| 2 | TECH |
BIO-TECHNE Corp
|
423 | $29,884 | |
| 3 | AVXL |
Anavex Life Sciences Corp.
|
3,000 | $7,770 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15 | $7,450 | |
| 5 | MRNA |
Moderna, Inc.
|
87 | $6,092 | |
| 6 | RPRX |
Royalty Pharma plc
|
98 | $5,494 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
10 | $3,010 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
22 | $1,258 |
All Filings in LGND
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $42,039 | 133 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $26,553 | 133 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $25,146 | 133 | Shares | Sole | 2026-02-02 | |
| 2025-09-30 | $23,559 | 133 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $15,119 | 133 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $13,983 | 133 | Shares | Sole | 2025-05-05 | |
| 2024-12-31 | $14,250 | 133 | Shares | Sole | 2025-02-11 | |
| No filing history on record for this holder in this stock. | ||||||